Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease.

CNS Drugs · 2023 · PMC10439019 · PMID 37470978

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Topline results from the phase III trial demonstrated a highly significant slowing of clinical decline as measured by the CDR-SB, with concordant results on all key secondary outcomes [ 22 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.